Overexpression of Golgi phosphoprotein-3 (GOLPH3) in glioblastoma multiforme is associated with worse prognosis

• DOI: 10.1007/s11060-012-0970-9
• Publication Date: 2012-09-12T12:20:18Z
• Authors: Jinxu Zhou; Tao Xu; Rong Qin; Yong Yan; Chao Chen; Yuanyuan Chen; Hongyu Yu; Chunyan Xia; Yicheng Lu; Xuehua Ding; Yuhai Wang; Xuejian Cai; Juxiang Chen
• Keywords: Male; 0301 basic medicine; Brain Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Blotting, Western; Membrane Proteins; Middle Aged; Prognosis; Real-Time Polymerase Chain Reaction; Immunoenzyme Techniques; Survival Rate; 03 medical and health sciences; 0302 clinical medicine; Tissue Array Analysis; Tumor Cells, Cultured; Humans; Female; RNA, Messenger; Neoplasm Grading; RNA, Small Interfering; Glioblastoma; Cell Proliferation; Follow-Up Studies

Golgi phosphoprotein-3 (GOLPH3), an important protein in mammalian target of rapamycin (mTOR) signaling, is overexpressed in and correlates with the pathological grade of glioma. However, the potential correlation between GOLPH3 and clinical outcome in patients with glioblastoma multiforme (GBM) remains unknown. In this study, we examined GOLPH3 expression in GBM by tissue microarray and correlated this measure to patient outcome. GOLPH3 expression in tumor tissue from 97 primary GBM patients was examined by tissue microarray and immunohistochemistry. Potential effects of GOLPH3 on tumor growth were also examined in representative cell lines (U251 and U87) by downregulating GOLPH3 with RNA interference. For this cohort, the median overall survival (OS) was 12 months [95 % confidence interval (CI): 10.31-13.69 months], and the median progression-free survival (PFS) was 10 months (95 % CI: 7.33-12.67 months). Tissue microarray analysis revealed high GOLPH3 expression in 40 patients (40/97, 41.2 %) and low GOLPH3 expression in the remaining 57 patients (57/97, 58.8 %). Log-rank test showed that patients with low GOLPH3 expression had significantly longer median OS (15 versus 10 months in patients with high GOLPH3 expression, p = 0.009) and median PFS (12 versus 7 months, p = 0.015). Univariate and Cox analysis indicated that GOLPH3 was an independent prognostic factor for OS and PFS. In in vitro experiments, GOLPH3 downregulation by small interfering RNA (siRNA) suppressed proliferation and clonogenic growth in cultured cell lines. These findings demonstrate that high GOLPH3 expression is associated with poor outcome of GBM patients.